12367 Version Date: 10/24/2017 Version: 09 For a tabular view of the treatment, monitoring, and follow-up schedule, see study calendar in Section 10. 5.2 Planned Duration of Therapy 5.2.1 Therapeutic portion of the protocol will last 6 weeks for Arm A patients, and 8 weeks for Arm B patients. 5.2.2 Criteria for Removal from Treatment Treatment may continue until one of the following criteria applies:  Completion of 3 courses of Sipuleucel-T  Symptomatic disease progression  Intercurrent illness that prevents further administration of treatment,  Unacceptable adverse event(s),  Patient decides to withdraw from the study,  General or specific changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator  Treatment delays of > 2 weeks due to adverse events.  Patient’s preference 5.3 Subject Follow- Up Foll owing completion of therapy patients will be followed clinically and will undergo periodic laboratory and radiographic tests until week 60 or until disease progression requiring additional therapy (see Study ca lendar 10.0) 5.4 Supportive Care, Other Concomitant Therapy, Prohibited Medications A pproximately 30 minutes prior to infusion of Sipuleucel- T subjects must be premedicated with acetaminophen (650 mg) and an antihistamine such as diphenhydramine (Benadryl®, 50 mg). Common treatment-related AEs such as pyrexia and/or rigors may warrant reduction of the infusion rate.